EASL | The Home of Hepatology

The #EASLCongress 2025 is your chance to engage with cutting-edge science, hands-on training, and world-class experts in hepatology! Taking place on 7–10 May in Amsterdam & online, this year’s congress is designed to be an immersive and dynamic experience, equipping you with the latest knowledge and practical skills to advance patient care. ⭐ Have you registered? https://lnkd.in/eJhBi5FY 📄 Explore our diverse scientific programme: https://lnkd.in/ekbWvChi 🔬 STATE-OF-THE-ART – Stay ahead of the curve with renowned experts presenting the latest breakthroughs shaping hepatology. 🤝 MEET-THE-EXPERTS – Get up close with key opinion leaders in an informal setting to discuss specialised topics. 💡 SKILLS LEARNING CENTRES – Take part in hands-on sessions to refine your practical skills and gain real-world expertise. 🚀 FUTURE OF HEPATOLOGY – Explore the next frontier with discussions on telemedicine, AI, and the evolution of liver care. ....and much more! Secure your spot! Aleksander Krag Debbie Shawcross

Happening TODAY! In the fourth edition of the EASL DeepDive series, join renowned experts Ana Lleo, Christophe Corpechot, Gideon Hirschfield, and Bettina Hansen as they explore the future of primary biliary cholangitis (PBC) treatment. 📅TODAY, 25 February ¦ 18:00 CET 🔗https://lnkd.in/d_tDqK5c

What’s next in the fight against hepatocellular carcinoma (HCC)? Join this #EASLStudio episode to gain a clinical perspective on advancing HCC care. Explore: ✅ The potential of adjuvant therapies ✅ Emerging molecular targets ✅ Strategies for curative conversion 📅Wednesday, 26 February ¦ 18:00 CET 🔗https://lnkd.in/d7qMchu6

Register now for next week's EASL DeepDive on the future of PBC Treatment. Faculty Ana Lleo, Adriaan van der Meer, Gideon Hirschfield, and Bettina Hansen will discuss emerging therapies, current challenges and personalised approaches that are shaping the management of PBC. 🗓️ Tuesday 25 February, 18:00 CET 🔗 https://lnkd.in/drU-AXuD

The EASL #LiverCancerSummit 2025 comes to a close! ⭐ We want to express our heartfelt gratitude to our faculty, delegates, and industry partners. The Summit was a great success, counting 720 delegates from 51 countries, 45 faculty members, 12 EASL Sessions and 238 abstracts submitted. Together, we've broadened our collective understanding of liver tumours and advanced the frontiers of research. View all photos here: https://lnkd.in/dyNuHe6K See you next time 🎗️ !

Time for another #EASLQuiz! 🧑⚕️A 74-year-old with HCV-related compensated cirrhosis (Child-Pugh A, MELD-Na 8) presents with a 37 mm LI-RADS 5 lesion in S5, no macrovascular invasion, and no extrahepatic spread. AFP: 106 ng/dL. Read the rest of the case and submit your answer! 🔗https://lnkd.in/dWxuayCv

❤️Bonjour from Paris! We're all set and ready to kick off the EASL #LiverCancerSummit which will take place over the next 3 days! 🎗️ Experts, researchers, and healthcare professionals from around the globe are gathered here to share insights, innovations, and advancements in liver cancer care. Aleksander Krag Rocio IR Macias Fabio Piscaglia Julien Calderaro Debbie Shawcross

In today's #readoftheweek📚 learn about the ALNE model and how it generates quantitative and accurate differential diagnosis between cases with autoimmune hepatitis or primary biliary cholangitis. Read here this JHEP Reports article: https://lnkd.in/eWEd3Rqb 🙏 to authors Alessio Gerussi, Dr. Oliver Lester Saldanha, Giorgio Cazzaniga, Damiano Verda, Zunamys Carrero, PhD, Bastian Engel, Richard Taubert, Francesca Bolis, Laura Cristoferi, Federica Malinverno, Francesca Colapietro, Reha Akpinar, Luca Di Tommaso, Luigi Terracciano, Ana Lleo, Mauro Viganó, Cristina Rigamonti, daniela cabibi, Vincenza Calvaruso, Fabio Gibilisco, Nicoló Caldonazzi, Alessandro Valentino, Stefano Ceola, Valentina Canini, Eugenia Nofit, Marco Muselli, Julien Calderaro, Dina Tiniakos, Vincenzo L’Imperio, Fabio Pagni, Nicola Zucchini, Pietro Invernizzi, Marco Carbone, and Jakob Nikolas Kather. ERN RARE-LIVER Università degli Studi di Milano-Bicocca Technische Universität Dresden Uniklinik RWTH Aachen Fondazione IRCCS San Gerardo dei Tintori

🌟 What is THRIVE? 🌟 THRIVE is a groundbreaking EU-funded initiative focused on understanding tumor-host interactions in liver cancer, spanning both childhood and adult cases. With 13 partners from 8 countries, the project brings together top multidisciplinary experts in liver cancer research, leveraging cutting-edge technologies to pave the way for innovative solutions. Discover more about our mission and approach here: https://lnkd.in/evv2T9hf #LiverCancer #CancerResearch #THRIVEProject #EUResearch #HealthcareInnovation #TeamScience Fundació Clínic per a la Recerca Biomèdica, EBERHARD-KARLS-UNIVERSITAT TUBINGEN, Université Paris Cité, Leiden University Medical Center, Weizmann Institute of Science, Krebsinformationsdienst, Deutsches Krebsforschungszentrum, European Liver Patients' Association - ELPA, EASL | The Home of Hepatology, Josep Carreras Leukaemia Research Institute (IJC), Newcastle University, Germans Trias i Pujol Research Institute (IGTP), Innovation Acta S.r.l., EASL the home of Hepatology Childhood Liver Oncology group Roser Pinyol, Quentin M. Anstee, Mathias Heikenwaelder, Sven Nahnsen, Manfred Claassen, Jessica Zucman-Rossi, Manel Esteller, Georg Zeller, Carolina Armengol, Eran Elinav, Jens Puschhof, Paola Cesaroni, Emily Mavin, DANA BERSTEIN, Wouter Kruijs, Chiara Hartmann, Adonia Dhanjal

🚨Due to high demand, onsite registration for the EASL #LiverCancerSummit 2025 is now at full capacity. 🚨 You can still participate online and gain full access to science, expert discussions and the latest advancements in the field. 🌎Engage with the full scientific programme from anywhere in the world. 👁️Watch sessions in real-time or catch up at your convenience. 💬Ask your questions and participate in discussions. Ensure your place at the summit by registering for online access today. https://lnkd.in/gU2EbQ23